ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0566

Healthcare Utilization and Costs Prior to Diagnosis of ANCA Vasculitis in Medicare Beneficiaries

Shirley Huang1, Xintong Li2, Joehl Nguyen2, Jacob Robinson2, Susan Hogan3, Vimal Derebail3 and Carolyn Thorpe2, 1University of North Carolina at Chapel Hill, Chapel Hill, 2University of North Carolina Eshelman School of Pharmacy, Chapel Hill, 3University of North Carolina Kidney Center, Chapel Hill

Meeting: ACR Convergence 2020

Keywords: Administrative Data, ANCA associated vasculitis, Economics, population studies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) vasculitis (AV) is a complex group of autoimmune disorders affecting blood vessels in multiple organ systems. Delays in diagnosis are common because AV symptoms can be non-specific and present heterogeneously. This may result in increased healthcare utilization in the months preceding diagnosis. We examined whether Medicare beneficiaries with AV experience increased healthcare utilization and costs in the year before the first diagnosis was recorded in claims, relative to Medicare beneficiaries without AV.

Methods: This retrospective cohort study used 2015-16 Medicare Part A/B medical claims and Part D prescription drug data. Beneficiaries with newly diagnosed AV were identified by having ≥1 inpatient claim or ≥2 non-inpatient claims at least 7 days apart in 2016 with an ICD-10 code for granulomatosis with polyangiitis, microscopic polyangiitis, or eosinophilic granulomatosis with polyangiitis, with no AV claims in the year prior. Beneficiaries with AV were matched 1:1 on age and sex to beneficiaries without any diagnosis codes for any type of systemic vasculitis in 2016. The study index date for AV beneficiaries was the first AV claim in 2016, which also served as the index date for the matched control. Beneficiaries were required to have continuous enrollment in Parts A, B, and D in the year prior to index. Outcomes included annual Medicare and beneficiary expenditures for Part A/B medical services, Part B and D medications, and annual counts of events in 12 categories of medical services (e.g., inpatient stays, outpatient visits, tests), for the year prior to the index date. Linear regression was used to test for differences, controlling for race/ethnicity, dual Medicaid enrollment or the Part D low-income subsidy, entitlement due to disability, and US region. Bias-corrected bootstrapped standard errors were used to calculate 95% confidence intervals (CI), accounting for non-normal distributions of dependent variables.

Results: A total of 1,626 AV beneficiaries and 1,626 matched controls met study criteria (mean age = 70.4 years, 62% female). The mean (SD) unadjusted Medicare and beneficiary Part A/B payments in the year prior to diagnosis were $23,445.23 (33,646.70) and $4,380.64 (5,064.45) for AV beneficiaries, respectively, and $10,136.05 (19,944.70) and $1,907.44 (3,292.49) for matched controls (Table 1). Adjusted regression analyses revealed that AV beneficiaries had significantly higher Medicare and beneficiary payments for all cost categories, and higher number of all types of utilization events, compared to matched controls (p< 0.001).  Of note, AV beneficiaries on average incurred an additional $13,726 (95% CI: $11,946-$15,845) in Medicare Part A/B expenditures and had 21.2 (95% CI: 18.3-24.5) more hospital outpatient visits vs. matched controls.

Conclusion: In the year prior to AV diagnosis, Medicare beneficiaries have significantly higher healthcare utilization and costs when compared to age- and sex-matched beneficiaries without AV. This study highlights that pre-diagnosis manifestations in AV can be costly and further improvement may be needed to allow for timely diagnosis.

Table 1. Total one-year utilization and costs prior to diagnosis for AV beneficiaries and matched controls


Disclosure: S. Huang, GlaxoSmithKline, 1; X. Li, None; J. Nguyen, Bristol Myers Squibb, 1; J. Robinson, None; S. Hogan, None; V. Derebail, Novartis, 1, Retrophin, 1; C. Thorpe, None.

To cite this abstract in AMA style:

Huang S, Li X, Nguyen J, Robinson J, Hogan S, Derebail V, Thorpe C. Healthcare Utilization and Costs Prior to Diagnosis of ANCA Vasculitis in Medicare Beneficiaries [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/healthcare-utilization-and-costs-prior-to-diagnosis-of-anca-vasculitis-in-medicare-beneficiaries/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/healthcare-utilization-and-costs-prior-to-diagnosis-of-anca-vasculitis-in-medicare-beneficiaries/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology